Armata Pharmaceuticals, Inc. (ARMP) stock
ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.99−0.88 (-22.74%)
Close on Nov 16, 2026Market cap $111.17MP/E –Yield –
Armata Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Armata Pharmaceuticals's total assets was $84.48M at Sep 30, 2026. For fiscal 2025 it was $76.88M, down 11.1% from the year before. Over ten years it grew 9.3% a year on average. The highest annual figure on record is $98.36M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.88M | -11.1% |
| FY2024 | Dec 31, 2024 | $86.44M | -12.1% |
| FY2023 | Dec 31, 2023 | $98.36M | +2.6% |
| FY2022 | Dec 31, 2022 | $95.83M | +37.4% |
| FY2021 | Dec 31, 2021 | $69.77M | +76.6% |
| FY2020 | Dec 31, 2020 | $39.52M | +55.3% |
| FY2019 | Dec 31, 2019 | $25.45M | +75.0% |
| FY2018 | Dec 31, 2018 | $14.55M | +30.6% |
| FY2017 | Dec 31, 2017 | $11.14M | -38.6% |
| FY2016 | Dec 31, 2016 | $18.15M | -42.4% |
| FY2015 | Dec 31, 2015 | $31.49M | +10.0% |
| FY2014 | Dec 31, 2014 | $28.62M | -30.6% |
| FY2013 | Dec 31, 2013 | $41.21M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $84.48M | -5.6% |
| Q2 FY2026 | Jun 30, 2026 | $89.95M | +11.3% |
| Q1 FY2026 | Mar 31, 2026 | $69.80M | -20.0% |
| Q4 FY2025 | Dec 31, 2025 | $76.88M | -11.1% |
| Q3 FY2025 | Sep 30, 2025 | $89.52M | -8.9% |
| Q2 FY2025 | Jun 30, 2025 | $80.79M | -25.4% |
| Q1 FY2025 | Mar 31, 2025 | $87.25M | -27.5% |
| Q4 FY2024 | Dec 31, 2024 | $86.44M | -12.1% |
| Q3 FY2024 | Sep 30, 2024 | $98.24M | -12.9% |
| Q2 FY2024 | Jun 30, 2024 | $108.31M | +7.0% |
| Q1 FY2024 | Mar 31, 2024 | $120.36M | +10.6% |
| Q4 FY2023 | Dec 31, 2023 | $98.36M | +2.6% |
| Q3 FY2023 | Sep 30, 2023 | $112.76M | +21.4% |
| Q2 FY2023 | Jun 30, 2023 | $101.21M | +0.2% |
| Q1 FY2023 | Mar 31, 2023 | $108.78M | +0.9% |
| Q4 FY2022 | Dec 31, 2022 | $95.83M | +37.4% |
| Q3 FY2022 | Sep 30, 2022 | $92.88M | +117.7% |
| Q2 FY2022 | Jun 30, 2022 | $100.98M | +109.2% |
| Q1 FY2022 | Mar 31, 2022 | $107.77M | +103.9% |
| Q4 FY2021 | Dec 31, 2021 | $69.77M | +76.6% |
| Q3 FY2021 | Sep 30, 2021 | $42.67M | -6.6% |
| Q2 FY2021 | Jun 30, 2021 | $48.28M | -2.4% |
| Q1 FY2021 | Mar 31, 2021 | $52.85M | +19.8% |
| Q4 FY2020 | Dec 31, 2020 | $39.52M | +55.3% |
| Q3 FY2020 | Sep 30, 2020 | $45.68M | +55.9% |
| Q2 FY2020 | Jun 30, 2020 | $49.46M | +41.7% |
| Q1 FY2020 | Mar 31, 2020 | $44.10M | +358.6% |
| Q4 FY2019 | Dec 31, 2019 | $25.45M | +75.0% |
| Q3 FY2019 | Sep 30, 2019 | $29.30M | +176.0% |
| Q2 FY2019 | Jun 30, 2019 | $34.92M | +197.9% |
| Q1 FY2019 | Mar 31, 2019 | $9.62M | -33.2% |
| Q4 FY2018 | Dec 31, 2018 | $14.55M | +30.6% |
| Q3 FY2018 | Sep 30, 2018 | $10.62M | -22.9% |
| Q2 FY2018 | Jun 30, 2018 | $11.72M | -22.4% |
| Q1 FY2018 | Mar 31, 2018 | $14.40M | +0.7% |
| Q4 FY2017 | Dec 31, 2017 | $11.14M | -38.6% |
| Q3 FY2017 | Sep 30, 2017 | $13.78M | – |
| Q2 FY2017 | Jun 30, 2017 | $15.11M | – |
| Q1 FY2017 | Mar 31, 2017 | $14.30M | – |
| Q4 FY2016 | Dec 31, 2016 | $18.15M | – |
See a number that looks wrong?